• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Solriamfetol
    1 Drug classified under this active ingredient


    All the Active Ingredient Drugs

    SUNOSI
    Neopharm Ltd, Israel
    RX
    partial basket chart
    SUNOSI

    Centrally Acting Sympathomimetics. Solriamfetol 75 mg, 150 mg.
    FC tabs  7,28,56 X 75/150 mg
    Narcolepsy:
    recomm. starting dose is 75 mg 1/d, max dd is 150 mg
    OSA: recomm. starting dose is 37.5 mg 1/d, max dd is 150 mg

    To improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy (with or w/ot cataplexy).
    Also to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA ther., such as CPAP.

    C/I:
     Hypersens. /MI within the past year, unstable angina pectoris, uncontrolled HT serious cardiac arrhythmias and other serious heart problems/
    Concom. use of MAOI or within 14 days after MAOI has been discontinued

    CLOSE